An alternative to treat depression-like behaviors: The effects of S-mecamylamine in the dorsal raphe nucleus
Andrea Mondragon Garcia, Enrique Ramírez-Sánchez, Daniela Francia-Ramírez, Fabiola Hernández-Vázquez, Julieta Garduno, Salvador Hernández-López · FENS Forum 2024
Around 280 million people worldwide suffer from depression. However, treatment for this mood disorder is ineffective in 30% of patients. An important target for the treatment of depression is the dorsal raphe nucleus (DRN), which is the main source of serotonin (5-HT) to the forebrain. Previous research has shown that mecamylamine (Mec) increases the activity of 5-HT neurons by enhancing glutamate release through activation of α4β2 nicotinic receptors (nAChRs), while inhibiting GABAergic release by inhibiting α7 nAChRs in the DRN. This mechanism may explain its antidepressant properties. Howev
ePoster · Neuroscience